The Proprotein Convertase Subtilisin/Kexin Type 9 pipeline drugs market research report outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Proprotein Convertase Subtilisin/Kexin Type 9 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Cardiovascular, Oncology, and Immunology which include the indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Non-Small Cell Lung Cancer, Follicular Lymphoma, and Inflammation. It also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 targeted therapeutics development with respective active and dormant or discontinued products.
The Proprotein Convertase Subtilisin/Kexin Type 9 pipeline targets constitutes close to 54 molecules. Out of which, approximately 51 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 8, 6, 13, 1, 1, 13, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Proprotein Convertase Subtilisin/Kexin Type 9 overview
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner.
For a complete picture of Proprotein Convertase Subtilisin/Kexin Type 9’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
